Reversal of cancer multidrug resistance by tea polyphenol in KB cells

Journal of Chemotherapy

Volumn 15, Issue 3, 2003, Pages 260-265

  Mei, Y ^a   Wei, Dongzhi ^a   Liu, J ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

( ) epigallocate chin gallate; Doxorubicin; Modulation; Multidrug resistance; Tea polyphenol

Indexed keywords

COLCHICINE; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; POLYPHENOL; VINBLASTINE;

ARTICLE; CANCER; CELL COUNT; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PHENOTYPE; TEA;

EID: 0038007511     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.3.260     Document Type: Article

References (26)

1. Simon SM, Schindler M. Cell biological mechanism of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 3497-3504.
2. Gao YT, Mc Laughlin JK, Blot WJ, Ji BT, Dai Q, Fraumeni Jr JF. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 1994; 86: 855-858.
3. Dreosti IE, Wargavich MJ, Yang CS. Inhibition of carcinogenesis by tea: the evidence from experimental studies. Crit Rev Food Sci Nutr 1997; 37: 761-770.
4. Kato I, Tominaga S, Matsuura A, Yoshii Y, Shirai M, Kobayashi S. A comparative case-control study of colorectal cancer and adenoma. Jpn J Cancer Res 1990; 81: 1101-1108.
5. Huang MT, Ho CT, Wang ZY, et al. Inhibitory effects of topical application of a green tea polyphenol fraction on tumor initiation and promotion in mouse skin. Carcinogenesis 1992; 13: 947-954.
6. Katiyar SK, Mukhtar H. Tea in chemoprevention of cancer, epidemiologic and experimental studies. Int J Oncol 1996; 8: 221-238.
7. Narasiwa T, Fukaura Y. A very low dose of green tea polyphenols in drinking water prevents N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1993; 84: 1007-1009.
8. Zloch Z. The role of dietary plant polyphenols in health maintenance. Cas Lek Cesk 1996; 135: 84-88.
9. Weisburger JH. Tea and health: the underlying mechanisms. Proc Soc Exp Biol Med 1999; 220: 271-275.
10. Buschman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer 1998; 31: 151-159.
11. Yu GP, Hsieh CC, Wang LY, Yu SZ, Li XL, Jin TH. Green-tea consumption and risk of stomach cancer - a population-based case-control study in Shanghai, China. Cancer Causes Control 1995; 6: 532-538.
12. Yasuyuki S, Tomomoi S, Takashi S. Efficacies of tea components on doxorubicin induced anticancer activity and reversal of multidrug resistance. Toxicol Lett 2000; 114: 155-162.
13. Gerd S, Manfred V. Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxombicin in drug-resistance cell lines. Anticancer Drugs 1997; 8: 265-268.
14. Sugiyama K, Ueda H. Protective effects of tea on toxic side platinum effects by anticancer drug, cisplatin in mice. Proc International Symposium on Tea Science 1991; 352: 26-29.
15. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993; 85: 1038-1049.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
17. Rajesh K, Lawrence DM. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
18. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res 1994; 54: 1969S-1975S.
19. Hao XY, Widersten M, Ridderstorm M, Hellamn U, Mamervik B. Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: Establishment of class Mu glutasthione transferase M3-3 as the domination isoenzyme. Biochem J 1994; 297: 59-67.
20. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992; 50: 760-766.
21. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R. Overexpression of P-glycoprotein and alterations in topoisomerase II in p388 mouse leukaemia cells selected in vivo for resistance to metoxantrone. Biochem Pharmacol 1992; 44: 937-945.
22. Borst P, Kool PM, Evers R. Do cMOAT (MRP2), other MRP homologues and LRP play a role in MDR. Cancer Biol 1997; 8: 205-213.
23. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein increases resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
24. Chambers T, Mcavoy E, Jacobs J, Eilon G. PKC phosphorylates P-glycoprotein in MDR human KB carcinoma cells. J Biol Chem 265: 7679-86, 1990.
25. ++-phospholipid-dependent protein kinase (protein kinase C). Biochem Biophys Res Commun 1989; 162: 903-907.
26. Sahyoun N, Wolf M, Besterman J, et al. Protein kinase C phophorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 1986; 83: 1603-1607.